e-Therapeutics plc Director Dealing and Issue of Equity (1398Z)
10 1월 2024 - 1:04AM
UK Regulatory
TIDMETX
RNS Number : 1398Z
e-Therapeutics plc
09 January 2024
e-therapeutics plc
("e-therapeutics" or the "Company")
Director Dealing and Issue of Equity
London, UK, 9 January 2024 - e-therapeutics plc (AIM: ETX;
OTCQX; ETXPF), a company integrating computational power and
biological data to discover life-transforming RNAi medicines, today
announces that on 9 January 2024, Professor Trevor Jones
(Non-Executive Chairman of the Company) subscribed for a total of
91,325 new ordinary shares of 0.1p each in the Company (the "New
Ordinary Shares") at a price of 8.28 pence per share. The
subscription monies paid for the New Ordinary Shares represent 50%
of Professor Jones' Non-Executive Director fees net of tax paid
during the period from 1 July 2023 to 31 December 2023 in
accordance with the agreement entered into with Professor Jones,
previously announced on 5 October 2016, by which Professor Jones
agreed, with effect from 1 October 2016, to invest 50% of his
annual Non-Executive Director fees net of tax in new
e-therapeutics' ordinary shares. Such new shares are issued to
Professor Jones on the first business day after 31 December and 30
June in each year. The subscription price to be paid is the average
of the closing mid-market price for the five business days prior to
the date of issue.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur at 8:00 a.m. on or around 15 January 2024. The
New Ordinary Shares will rank pari passu in all respects with the
Company's existing ordinary shares in issue.
Following Admission, Professor Jones will be interested in a
total of 1,293,896 ordinary shares of 0.1p in the Company,
representing approximately 0.22% of the Company's issued share
capital.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 583,935,487. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Trevor Jones
-------------------------- -------------------------------------------
Reason for the notification
2
-----------------------------------------------------------------------
a) Position/status Non-Executive Chairman
-------------------------- -------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- -------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name e-therapeutics plc
-------------------------- -------------------------------------------
b) LEI 21380049RHSSJXWKYT18
-------------------------- -------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence
financial instrument,
type of instrument ISIN: GB00B2823H99
Identification code
-------------------------- -------------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- -------------------------------------------
c) Price(s) and volume(s) 9 1,325 ordinary shares at a price of 8.28
pence per share
-------------------------- -------------------------------------------
d) Aggregated information 91,325 ordinary shares
- Aggregated volume 8.28 pence per share
- Price Aggregated value: GBP7,561.71
-------------------------- -------------------------------------------
e) Date of the transaction 9 January 2024
-------------------------- -------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -------------------------------------------
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)20 4551
Timothy Bretherton, CFO 8888
www.etherapeutics.co.uk
------------------------------------------------ -------------------------
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
------------------------------------------------ -------------------------
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and
biology information to discover life-transforming RNAi medicines.
The Company's technology uses computation to capture and model
human biology, identify novel targets, and develop RNAi medicines
against those targets that can be rapidly progressed to the
clinic.
ETX's proprietary HepNet(TM) platform enables the generation and
analysis of biological network models, providing a novel and
mechanistic approach to drug discovery. This approach explicitly
considers the true complexity of biology to make more reliable
predictions from large complex data sets and ETX's proprietary
hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource. The Company generates,
prioritises, and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.
GalOmic(TM), ETX's proprietary RNAi platform, enables targeted
delivery to hepatocytes in the liver and the specific silencing of
novel disease-associated genes, identified by HepNet(TM). The focus
on hepatocytes offers the opportunity to tackle a wide variety of
diseases. The liver is a highly metabolically active organ which
performs a key role in many biological processes and vital
functions crucial for human health. ETX's GalOmic(TM) constructs
have demonstrated compelling in vivo performance in terms of depth
of gene silencing and duration of action.
The Company is progressing a pipeline of first-in-class RNAi
candidates across a variety of therapeutic areas with high unmet
need, including preclinical programs in cardiometabolic and
metabolic diseases, haemophilia, and other undisclosed indications.
ETX has also partnered with biopharma companies such as Novo
Nordisk, Galapagos NV and iTeos Therapeutics using its
computational network biology approach across a diverse range of
drug discovery projects.
The Company is based in London, UK and listed on the Alternative
Investment Market of the London Stock Exchange ("AIM"), with ticker
symbol ETX.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFIRLVIAIIS
(END) Dow Jones Newswires
January 09, 2024 11:04 ET (16:04 GMT)
E-therapeutics (LSE:ETX)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
E-therapeutics (LSE:ETX)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
